{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["apoptotic effects", "corilagin", "epithelial ovarian cancer", "gene ontology"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "28408846", "DateRevised": {"Year": "2022", "Month": "01", "Day": "12"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "03", "Day": "31"}], "Language": ["eng"], "ELocationID": ["10.2147/OTT.S135315"], "Journal": {"ISSN": "1178-6930", "JournalIssue": {"Volume": "10", "PubDate": {"Year": "2017"}}, "Title": "OncoTargets and therapy", "ISOAbbreviation": "Onco Targets Ther"}, "ArticleTitle": "Apoptotic and genomic effects of corilagin on SKOV3 ovarian cancer cell line.", "Pagination": {"StartPage": "1941", "EndPage": "1946", "MedlinePgn": "1941-1946"}, "Abstract": {"AbstractText": ["Corilagin is a member of the tannin family and has been isolated from traditional Chinese medicinal plants, such as <i>Phyllanthus</i> spp. Corilagin has anti-inflammatory, antioxidative, antiatherogenic, and antihypertensive effects in various experimental models. In this research, we aimed to investigate for the first time whether corilagin had apoptotic and genomic effects in ovarian cancer treatment in the same study. The potential apoptotic of corilagin was investigated using a WST1 cell proliferation test, caspase 3, and mitochondrial membrane potential JC1 assays in a time- and dose-dependent manner. Genomic changes in expression levels against corilagin treatment were measured using an Illumina human HT-12V4 BeadChip microarray. Bioinformatic data analyses were performed using GenomeStudio and Ingenuity Pathway Analysis software. The data of our study demonstrated that there were statistically significant time- and dose-dependent increases in caspase 3 enzymatic activity and loss of mitochondrial membrane potential in line with decreases in cancer cell proliferation. According to gene-ontology analysis, we found that adherens junctions, antigen processing and presentation, and the phosphatidylinositol signaling system were the most statistically significant networks in response to corilagin treatment on SKOV3 cells, in a time- and dose-dependent manner. The apoptotic and genome-wide effects of corilagin on ovarian cancer cells were examined in detail for the first time in the literature. The results of our study suggest that corilagin might have the potential to be used as a new treatment option for epithelial ovarian cancer."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Obstetrics and Gynecology, Yeditepe University Hospital."}], "LastName": "Attar", "ForeName": "Rukset", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University."}], "LastName": "Cincin", "ForeName": "Zeynep Birsu", "Initials": "ZB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul Yeni Yuzyil University, Istanbul, Turkey."}], "LastName": "Bireller", "ForeName": "Elif Sinem", "Initials": "ES"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University."}], "LastName": "Cakmakoglu", "ForeName": "Bedia", "Initials": "B"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Onco Targets Ther", "NlmUniqueID": "101514322", "ISSNLinking": "1178-6930"}, "CoiStatement": "Disclosure The authors report no conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277\u2013300.", "ArticleIdList": ["20610543"]}, {"Citation": "Ren F, Shen J, Shi H, Hornicek FJ, Kan Q, Duan Z. Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer. Biochim Biophys Acta. 2016;1866(2):266\u2013275.", "ArticleIdList": ["27717733"]}, {"Citation": "Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519\u20132529.", "ArticleIdList": ["15590954"]}, {"Citation": "Deng J, Wang L, Chen H, et al. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget. 2016;7(34):55771\u201355788.", "ArticleIdList": ["PMC5342453", "27304054"]}, {"Citation": "Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.", "ArticleIdList": ["25651787"]}, {"Citation": "Cakmakoglu BA, Attar R, Kahraman OT, et al. Cyclooxygenase-2 gene and epithelial ovarian carcinoma risk. Mol Biol Rep. 2011;38(5):3481\u20133486.", "ArticleIdList": ["21107726"]}, {"Citation": "Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120(3):612\u2013618.", "ArticleIdList": ["22914471"]}, {"Citation": "Qin D, Wang W, Lei H, et al. CDDO-Me reveals USP7 as a novel target in ovarian cancer cells. Oncotarget. 2016;7(47):77096\u201377109.", "ArticleIdList": ["PMC5363571", "27780924"]}, {"Citation": "Vaughan S, Coward JI, Bast RC, Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719\u2013725.", "ArticleIdList": ["PMC3380637", "21941283"]}, {"Citation": "Qin DJ, Tang CX, Yang L, et al. Hsp90 is a novel target molecule of CDDO-Me in inhibiting proliferation of ovarian cancer cells. PLoS One. 2015;10(7):e0132337.", "ArticleIdList": ["PMC4489813", "26134508"]}, {"Citation": "Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013;19(5):961\u2013968.", "ArticleIdList": ["23307860"]}, {"Citation": "Hau DK, Gambari R, Wong RS, et al. Phyllanthus urinaria extract attenuates acetaminophen induced hepatotoxicity: involvement of cytochrome P450 CYP2E1. Phytomedicine. 2009;16(8):751\u2013760.", "ArticleIdList": ["19386480"]}, {"Citation": "Shen ZQ, Dong ZJ, Peng H, Liu JK. Modulation of PAI-1 and tPA activity and thrombolytic effects of corilagin. Planta Med. 2003;69(12):1109\u20131112.", "ArticleIdList": ["14750026"]}, {"Citation": "Sudjaroen Y, Hull WE, Erben G, et al. Isolation and characterization of ellagitannins as the major polyphenolic components of longan (Dimocarpus longan Lour) seeds. Phytochemistry. 2012;77:226\u2013237.", "ArticleIdList": ["22277734"]}, {"Citation": "Okabe S, Suganuma M, Imayoshi Y, Taniguchi S, Yoshida T, Fujiki H. New TNF-\u03b1 releasing inhibitors, geraniin and corilagin, in leaves of Acer nikoense, megusurinoki. Biol Pharm Bull. 2001;24(10):1145\u20131148.", "ArticleIdList": ["11642320"]}, {"Citation": "Duan W, Yu Y, Zhang L. Antiatherogenic effects of Phyllanthus emblica associated with corilagin and its analogue. Yakugaku Zasshi. 2005;125(7):587\u2013591.", "ArticleIdList": ["15997216"]}, {"Citation": "Cheng JT, Lin TC, Hsu FL. Antihypertensive effect of corilagin in the rat. Can J Physiol Pharmacol. 1995;73(10):1425\u20131429.", "ArticleIdList": ["8748933"]}, {"Citation": "Duan WG, Shen ZQ, Yan M, Yun Y, Zhang LY. Corilagin, a promising natural product to treat cardiovascular diseases. In: Singh VK, Mishra SK, Govil JN, editors. Phytopharmacology and Therapeutic Values II. Houston: Studium Press; 2008. pp. 163\u2013172."}, {"Citation": "Kinoshita S, Inoue Y, Nakama S, Ichiba T, Aniya Y. Antioxidant and hepatoprotective actions of medicinal herb, Terminalia catappa L. from Okinawa Island and its tannin corilagin. Phytomedicine. 2007;14(11):755\u2013762.", "ArticleIdList": ["17293097"]}, {"Citation": "Hau DK, Zhu GY, Leung AK, et al. In vivo anti-tumour activity of corilagin on HEP3B hepatocellular carcinoma. Phytomedicine. 2010;18(1):11\u201315.", "ArticleIdList": ["21036022"]}, {"Citation": "Gambari R, Hau DK, Wong WY, Chui CH. Sensitization of HEP3B hepatoma cells to cisplatin and doxorubicin by corilagin. Phytother Res. 2014;28(5):781\u2013783.", "ArticleIdList": ["23913631"]}, {"Citation": "Ming Y, Zheng Z, Chen L, et al. Corilagin inhibits hepatocellular carcinoma cell proliferation by inducing G2/M phase arrest. Cell Biol Int. 2013;37(10):1046\u20131054.", "ArticleIdList": ["23686743"]}, {"Citation": "Muresan XM, Cervellati F, Sticozzi C, et al. The loss of cellular junctions in epithelial lung cells induced by cigarette smoke is attenuated by corilagin. Oxid Med Cell Longev. 2015;2015:631758.", "ArticleIdList": ["PMC4354730", "25802682"]}, {"Citation": "Wang Z, Guo QY, Zhang XJ, et al. Corilagin attenuates aerosol bleomycin-induced experimental lung injury. Int J Mol Sci. 2014;15(6):9762\u20139779.", "ArticleIdList": ["PMC4100119", "24886817"]}, {"Citation": "Jia L, Jin H, Zhou J, et al. A potential anti-tumor herbal medicine, corilagin, inhibits ovarian cancer cell growth through blocking the TGF-\u03b2 signaling pathways. BMC Complement Altern Med. 2013;13:33.", "ArticleIdList": ["PMC3598193", "23410205"]}]}], "History": [{"Year": "2017", "Month": "4", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "4", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "4", "Day": "15", "Hour": "6", "Minute": "1"}, {"Year": "2017", "Month": "3", "Day": "31"}], "PublicationStatus": "epublish", "ArticleIdList": ["28408846", "PMC5384738", "10.2147/OTT.S135315", "ott-10-1941"]}}]}